ArticleThe European respiratory journal2022
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 60 citations in OpenAlex.
- Fucosyltransferases in asthma: regulators of epithelial dysfunction, senescence, and airway inflammation.Clinical reviews in allergy & immunology · 2026Review
- A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.The World Allergy Organization journal · 2026Article
- The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge.Journal of clinical medicine · 2026Review
- Review
- Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain.Journal of clinical medicine · 2026Article
- Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment.Journal of clinical medicine · 2026Review
- Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis.Frontiers in immunology · 2026Article
- Molecular Mechanisms Linking Eosinophils to Lung Function Impairment in Respiratory Diseases.Journal of asthma and allergy · 2026Review
- Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms.Journal of inflammation research · 2026Review
- Benralizumab: Bringing winds of change to eosinophil-associated diseases.The World Allergy Organization journal · 2025Review
- The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma.International journal of molecular sciences · 2025Review
- Robust evidence of the rapid efficacy of benralizumab.Journal of thoracic disease · 2025Article
- Achieving remission in severe asthma.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study.Journal of clinical medicine · 2025Article
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study.Journal of clinical medicine · 2025Article
- Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2025Article
- Review
- Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics.Journal of asthma and allergy · 2025Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenralizumab is a humanised, anti-interleukin-5 receptor α monoclonal antibody with anti-eosinophilic activity. Lack of fucose (afucosylation) increases its affinity to CD16a and significantly enhances antibody-dependent cell-mediated cytotoxicity by natural killer (NK) cells. Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remains elusive.
methodsHere, we further investigated the mechanisms involved in benralizumab's anti-eosinophilic activities by employing relevant primary human autologous cell co-cultures and real-time-lapse imaging combined with flow cytometry.
resultsIn the presence of NK cells, benralizumab induced potent eosinophil apoptosis as demonstrated by the upstream induction of Caspase-3/7 and upregulation of cytochrome
conclusionsOur data provide deeper insights into the timely appearance of events leading to benralizumab-induced eosinophil apoptosis and suggest that additional mechanisms may contribute to the potent anti-eosinophilic activity of benralizumab
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.